دورية أكاديمية

Therapeutic hypothermia in patients with coagulopathy following severe traumatic brain injury

التفاصيل البيبلوغرافية
العنوان: Therapeutic hypothermia in patients with coagulopathy following severe traumatic brain injury
المؤلفون: Toru Hifumi, Yasuhiro Kuroda, Kenya Kawakita, Susumu Yamashita, Yasutaka Oda, Kenji Dohi, Tsuyoshi Maekawa, on behalf of the Brain Hypothermia (B-HYPO) study group in Japan
المصدر: Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, Vol 25, Iss 1, Pp 1-8 (2017)
بيانات النشر: BMC, 2017.
سنة النشر: 2017
المجموعة: LCC:Medical emergencies. Critical care. Intensive care. First aid
مصطلحات موضوعية: Coagulopathy, Therapeutic hypothermia, Traumatic brain injury, Targeted temperature management, Fibrinogen degradation products, Medical emergencies. Critical care. Intensive care. First aid, RC86-88.9
الوصف: Abstract Background Coagulopathy in traumatic brain injury (TBI) has been associated with poor neurological outcomes and higher in-hospital mortality. In general principle of trauma management, hypothermia should be prevented as it directly worsens coagulopathy. Therefore, we examined the safety of mild therapeutic hypothermia (MTH) in patients with coagulopathy following severe TBI. Methods We re-evaluated the brain hypothermia (B-HYPO) study data based on coagulopathy and compared the Glasgow Outcome Scale scores and survival rates at 6 months using per protocol analyses. Coagulopathy was defined as an activated partial thromboplastin time (APTT) > 60 s and/or fibrin/fibrinogen degradation product levels (FDP) > 90 μg/mL on admission. Baseline characteristics, coagulation parameters, and outcomes were compared between the control and MTH groups with or without coagulopathy. Results In patients with coagulopathy, 12 patients were allocated to the control group (35.5–37.0 °C) and 20 patients to the MTH group (32–34 °C). In patients without coagulopathy, 28 were allocated to the control group and 59 patients were allocated to the MTH group. In patients with coagulopathy, favorable neurological outcomes and survival rates were comparable between the control and MTH groups (33.3% vs. 35.0%, P = 1.00; 50.0% vs. 60.0%, P = 0.72) with no difference in complication rates. On admission, no significant differences in APTT or FDP levels were observed between the two groups; however, APTT was significantly prolonged in the MTH group compared to the control group on day 3. Discussion Based on our study, MTH did not seem to negatively affect the outcomes in patients with coagulopathy following severe TBI on admission; therefore, the present study indicates that MTH may be applicable even in patients with severe TBI and coagulopathy. Conclusions Our study suggests that in comparison to control, MTH does not worsen the outcome of patients with coagulopathy following severe TBI. Trial registration UMIN-CTR, No. C000000231 , Registered 13 September 2005.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1757-7241
Relation: http://link.springer.com/article/10.1186/s13049-017-0465-y; https://doaj.org/toc/1757-7241
DOI: 10.1186/s13049-017-0465-y
URL الوصول: https://doaj.org/article/6c14e636db264aad977553b73e66da22
رقم الأكسشن: edsdoj.6c14e636db264aad977553b73e66da22
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:17577241
DOI:10.1186/s13049-017-0465-y